The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Mon., Jan. 24, 1:43 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #34. McKesson Corporation Celesio

Acquirer: McKesson Corporation (NYSE:MCK)
Acquiree: Celesio
Details: McKesson Corporation (NYSE:MCK), a leading North American healthcare services and information technology company, confirmed today that it has completed the previously announced agreement with Franz Haniel & Cie. GmbH to acquire their entire holding of Celesio shares. McKesson also confirmed it has completed the previously announced agreement with an affiliate of Elliott Management to acquire Celesio convertible bonds. McKesson now exceeds 75% ownership of Celesio shares on a fully diluted basis.

McKesson is engaged in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. Co.'s segments include: U.S. Pharmaceutical, which distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs; International, which provides distribution and services to wholesale, institutional, and retail customers; Medical-Surgical Solutions, which provides medical-surgical supply distribution, logistics, and other services to healthcare providers; and Prescription Technology Solutions, which brings together CoverMyMeds, RelayHealth, RxCrossroads, and McKesson Prescription Automation.

McKesson SEC Filing Email Alerts Service


Open the MCK Page at The Online Investor »

Company Name: 
McKesson Corp
Website: 
www.mckesson.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding MCK: 
104
Total Market Value Held by ETFs: 
$5.13B
Total Market Capitalization: 
$38.35B
% of Market Cap. Held by ETFs: 
13.37%
 

Open the MCK Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree MCK Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.59 out of 4)
50th percentile
(ranked higher than approx. 50% of all stocks covered)

Analysts' Target Price:
MCK Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 34 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.